Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.

Tu, Min; Li, Haifeng; Lv, Nan; Xi, Chunhua; Lu, Zipeng; Wei, Jishu; Chen, Jianmin; Guo, Feng; Jiang, Kuirong; Song, Guoxin; Gao, Wentao; Miao, Yi

Tu, Min; Li, Haifeng; Lv, Nan; Xi, Chunhua; Lu, Zipeng; Wei, Jishu; Chen, Jianmin; Guo, Feng; Jiang, Kuirong; Song, Guoxin; Gao, Wentao; Miao, Yi.

Afiliação

Tu M; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Li H; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Lv N; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Xi C; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Lu Z; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Wei J; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Chen J; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Guo F; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Jiang K; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Song G; Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Gao W; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China. gao11@hotmail.com.
Miao Y; Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China. miaoyi@njmu.edu.cn.

Mol Cancer ; 16(1): 66, 2017 03 21.

Article em En | MEDLINE | ID: mdl-28327155

Assuntos

Proteínas Angiogênicas/genética; Desoxicitidina/análogos & derivados; Resistencia a Medicamentos Antineoplásicos/genética; Neoplasias Pancreáticas/genética; Neoplasias Pancreáticas/metabolismo; Proteínas Proto-Oncogênicas c-jun/metabolismo; Ribonucleosídeo Difosfato Redutase/genética; Ativação Transcricional; Animais; Linhagem Celular Tumoral; Desoxicitidina/farmacologia; Modelos Animais de Doenças; Regulação Neoplásica da Expressão Gênica; Humanos; Estimativa de Kaplan-Meier; Masculino; Camundongos; Neoplasias Pancreáticas/mortalidade; Neoplasias Pancreáticas/patologia; Prognóstico; Regiões Promotoras Genéticas; Ligação Proteica; Proto-Oncogene Mas; Ensaios Antitumorais Modelo de Xenoenxerto; Gencitabina

Palavras-chave

Gemcitabine; Jun proto-oncogene; Pancreatic cancer; Ribonucleotide reductase regulatory subunit M2; Vasohibin 2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Ribonucleosídeo Difosfato Redutase / Ativação Transcricional / Proteínas Proto-Oncogênicas c-jun / Resistencia a Medicamentos Antineoplásicos / Proteínas Angiogênicas / Desoxicitidina Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google